Kidney Cancer

Robert Alter, MD comments on the use of prognostic models for determining risk status and informing treatment options in patients with RCC.

Laurence Albigès, MD, PhD, discusses how immunotherapy combinations have affected the treatment landscape for previously untreated advanced or metastatic renal cell carcinoma.

Laurence Albigès, MD, PhD, spotlighted 2-year follow-up data from the phase 3 CheckMate 9ER trial, which looked at nivolumab and cabozantinib in patients with previously untreated advanced or metastatic renal cell carcinoma.

Laurence Albigès, MD, PhD, speaks to how patients with treatment-naïve advanced or metastatic renal cell carcinoma can benefit from treatment with nivolumab and ipilimumab.

Laurence Albigès, MD, PhD, shares updated key findings from the phase 3 CheckMate 214 trial.

Gennady Bratslavsky, MD, spoke about the evolving field of surgery for renal cell carcinoma at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies.

Gennady Bratslavsky, MD, spoke about the evolution for treatments in renal cell carcinoma and how surgery may play a role.

Laurence Albigès, MD, PhD, speaks to the patient population included in the phase 3 CheckMate 214 trial, assessing nivolumab plus ipilimumab in patients with treatment-naïve advanced or metastatic renal cell carcinoma.

For Kidney Cancer Awareness Month, CancerNetwork® spoke with Daniel M. Geynisman, MD, about how emerging data in the treatment of renal cell carcinoma stand to further impact the standard of care.

Oncologists give their initial impressions about the results of a clinical trial studying doublet combination therapies for advanced renal cell carcinoma.

Robert J. Motzer, MD, presents data examined in the article, “Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.”

For Kidney Cancer Awareness Month, Toni K. Choueiri, MD, spoke with CancerNetwork® about ongoing trials clinicians need to be aware of.

Gennady Bratslavsky, MD, discusses the ever-changing field of treatment options for renal cell carcinoma at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, hosted by Physicians’ Education Resource®, LLC.

At 2022 ASCO GU, Toni K. Choueiri, MD, explained the data seen in the updated results from the KEYNOTE-564 trial for patients with renal cell carcinoma.

In recognition of Kidney Cancer Awareness Month, CancerNetwork® spoke with Laurence Albigès, MD, PhD, about immunotherapy combination trials for renal cell carcinoma that read out at the 2022 Genitourinary Cancers Symposium.

Primo Nery Lara, Jr., MD, talks treatment of metastatic renal cell carcinoma in the first-line setting at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, hosted by Physicians’ Education Resource®, LLC.

At 2022 ASCO GU, Daniel M. Geynisman, MD, spoke with CancerNetwork® about his strategy for treating renal cell carcinoma across lines of therapy.

For Kidney Cancer Awareness Month, CancerNetwork® spoke with Chung-Han Lee, MD, PhD, about research in renal cell carcinoma that has the greatest potential to impact the standard of care.

Chung-Han Lee, MD, PhD, spoke about necessary research needed moving forward for patients with metastatic renal cell carcinoma.

At 2022 ASCO GU, Toni K. Choueiri, MD, discussed the CLEAR study and how East Asian patients with renal cell carcinoma derived similar benefit with lenvatinib plus pembrolizumab as the overall trial population.

Chung-Han Lee, MD, PhD, spoke about interesting findings that arose from the KEYNOTE-146 study for patients with metastatic renal cell carcinoma.

Patients with metastatic renal cell carcinoma and a performance status of 2 or more experienced promising clinical activity from treatment with nivolumab/ipilimumab and pembrolizumab/axitinib.

The final analysis of the phase 3 IMmotion151 trial did not reveal a significant improvement in overall survival with atezolizumab plus bevacizumab over sunitinib for previously untreated patients with metastatic renal cell carcinoma.

Data from a phase 2 trial of atezolizumab with or without radiotherapy showed some antitumor activity in advanced squamous cell carcinoma of the penis, despite failing to meet the primary end point of progression-free survival.

Updated data from the KEYNOTE-564 trial that were reported at 2022 ASCO GU show continuous disease-free survival advantage with pembrolizumab vs placebo as adjuvant therapy for renal cell carcinoma.

Data from the NeoAvAx trial presented at 2022 ASCO GU show potential for neoadjuvant avelumab plus axitinib for high-risk, non-metastatic clear-cell renal cell carcinoma.

Retrospective trial results inform utility of tivozanib in the real-world treatment of renal cell carcinoma.

Better health-related quality of life outcomes were associated with nivolumab and cabozantinib for advanced renal cell carcinoma vs sunitinib.

A surrogate for toxicity and drug exposure, cabozantinib dose reductions were tied to longer durations of time to treatment failure and overall survival for patients with metastatic renal cell carcinoma.

Treatment with cabozantinib in the second line yielded responses in patients with advanced renal cell carcinoma who received immunotherapy in the frontline, regardless of prior regimen.